Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.

"Competing interests: SN has received speaking fees from Bristol-Myers, UCB, Astellas, Abbvie, Eisai, Pfizer, and Takeda, and also research grants from Mitsubishi-Tanabe, Novartis and MSD. SK has received speaking fees from Eli Lilly, Bristol-Myers, GlaxoSmithKline, Abbvie, and also research grants from Daiichi-Sankyo, Abbvie, Boehringer Ingelheim, and Astellas. YT has received consulting fees, speaking fees, and/or honoraria from Abbvie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers, Astellas, Eisai, Janssen, Pfizer, Asahi-Kasei, Eli Lilly, GlaxoSmithKline, UCB, Teijin, MSD and Santen, and also research grants from Mitsubishi-Tanabe, Takeda, Chugai, Astellas, Eisai, Taisho-Toyama, Kyowa-Kirin, Abbvie and Bristol-Myers."

"Funding: This study was supported in part by a Grant-In-Aid for Scientific Research from the University of Occupational and Environmental Health, Japan, through University of Occupational & Environmental Health, Japan (UOEH) for Advanced Research (19K17919). YO was supported by JSPS KAKENHI (22H00476), and AMED (JP22ek0410075, JP23km0405211, JP23km0405217, JP23ek0109594, JP23ek0410113, JP223fa627002, JP223fa627010, JP233fa627011, JP23zf0127008), JST Moonshot R&D (JPMJMS2021, JPMJMS2024), Takeda Science Foundation, Bioinformatics Initiative of Osaka University Graduate School of Medicine, Institute for Open and Transdisciplinary Research Initiatives, Center for Infectious Disease Education and Research (CiDER), and Center for Advanced Modality and DDS (CAMaD), Osaka University."